The long-running legal dispute between Amgen and Sanofi/Regeneron on two key patents covering the use of PCSK9 inhibitors to lower ... hefty royalties if they do so. In this case, the two patents ...

theheart.org on Medscape, April 18, 2016 PCSK9 Inhibitors for Statin Intolerance, Early Beta Blockade in AMI? Drs Harrington and Ohman debate PCSK9 inhibitors for statin intolerance and the use of ...

In the trial, 20% of patients didn’t respond well to the PCSK9 inhibitor—could genetic markers be used to tailor therapy?